Literature DB >> 15670222

Long-term endocrine effects of cancer treatment: experience of the Royal Children's Hospital, Melbourne.

R Hameed1, M R Zacharin.   

Abstract

OBJECTIVES: To evaluate the frequency and degree of severity of endocrine late effects in patients treated for childhood cancer and to assess the value of the late effects clinic for continued monitoring of these patients.
METHOD: Data was collected on all patients who attended the late effects clinic at the Royal Children's Hospital (RCH) between 1998-2003. Endocrine function was assessed by clinical and biochemical evaluation at the time of presentation and at ongoing intervals of 3-12 months as clinically indicated.
RESULTS: A total of 249 children attended the late effects clinic. Two hundred and thirty five endocrine diagnoses were made in 155 (62%) patients, of whom 63 patients had multiple endocrinopathies.
CONCLUSION: Our audit supports the need for ongoing prospective surveillance in survivors of childhood cancer. Appropriate and timely interventions in such patients can help to reduce morbidity and improve quality of life.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15670222     DOI: 10.1111/j.1440-1754.2005.00533.x

Source DB:  PubMed          Journal:  J Paediatr Child Health        ISSN: 1034-4810            Impact factor:   1.954


  3 in total

1.  Endocrine sequelae of cancer and cancer treatments.

Authors:  Charles J Stava; Camilo Jimenez; Rena Vassilopoulou-Sellin
Journal:  J Cancer Surviv       Date:  2007-11-20       Impact factor: 4.442

2.  Hypothalamic Obesity: 4 Years of the International Registry of Hypothalamic Obesity Disorders.

Authors:  Susan R Rose; Vincent E Horne; Nathan Bingham; Todd Jenkins; Jennifer Black; Thomas Inge
Journal:  Obesity (Silver Spring)       Date:  2018-10-08       Impact factor: 5.002

3.  Prevalence of Endocrine Disorders in Childhood Brain Tumor Survivors in South Korea.

Authors:  Jaesung Heo; Hae Sang Lee; Jin Son Hwang; O Kyu Noh; Logyoung Kim; Jun Eun Park
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.